Sphingomyelinase and cell-permeable ceramide analogs increase the release of plasminogen activator inhibitor-1 from cultured endothelial cells

Thrombosis Research

Volumn 80, Issue 6, 1995, Pages 509-518

  Soeda, Shinji ^a   Honda, Okinobu ^a   Shimeno, Hiroshi ^a   Nagamatsu, Atsuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

ceramide analog; plasminogen activator inhibitor 1; sphingomyelinase; vascular endothelial cell

Indexed keywords

CERAMIDE; CERAMIDE DERIVATIVE; CYCLOHEXIMIDE; DACTINOMYCIN; N ACETYL SPHINGOSINE; N HEXANOYL SPHINGOSINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CELL MEMBRANE PERMEABILITY; CERAMIDES; CYCLOHEXIMIDE; DACTINOMYCIN; ENDOTHELIUM, VASCULAR; HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN SYNTHESIS INHIBITORS; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE; SUPPORT, NON-U.S. GOV'T; UMBILICAL VEINS;

EID: 0028895009     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(95)00206-5     Document Type: Article

References (24)

1. Plasminogen activator inhibitors
2. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
3. Pregnancy-induced changes in the fibrinolytic balance: evidence for defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor
4. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
5. Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia
6. Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias. I. Increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins
7. Neutral sphingomyelinase from human urine: purification and preparation of monospecific antibodies
8. Sphingolipid breakdown products: antiproliferative and tumor-suppressor lipids
9. A rapid method of total lipid extraction and purification
10. Quantitation of lipids by carring on thin-layer plates and scintillation quenching: application to ceramide determination
11. 1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ
12. Quantitative densitometric thin-layer chromatography of lipids using copper acetate reagent
13. Sphingomyelinase and cell-permeable ceramide analogs stimulate cellular proliferation in quiescent Swiss 3T3 fibroblasts
14. The fibrinolytic system of the vascular wall
15. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor
16. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo
17. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells
18. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells
19. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation
20. 2 production and sphingomyelin metabolism
21. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells
22. Cachectin: more than a tumor necrosis factor
23. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β
24. Programmed cell death induced by ceramide